ATB-301

ATB-301
Product Description

[TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib

1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 

2. Confirm the suppression of IL-2’s side effect in combination therapy which is caused by increase of Treg 

3. Confirm the synergistic effects and mode of action of the combination therapy in in-vivo and Phase Ib clincal study T

4. Secure the safety and efficay of TGF-β2 targeting ASO by monotherapy upto phase 2 clinical trial
- No hepatotoxicity, skin toxicity, or cardiototicity were shown, which are common in Pan TGF-β inhibitors (small moldeules to block TGF-β signaling pathway, antibody against TGF-β1, 2, 3) 

Read more Show less

Autotelic Bio

  • KR
  • 2021
    On CPHI since
  • 25 - 49
    Employees
Company types
Manufacturer/Innovator
View company profile
Categories
more categories Show less

Autotelic Bio

  • KR
  • 2021
    On CPHI since
  • 25 - 49
    Employees
Company types
Manufacturer/Innovator
View company profile

More Products from Autotelic Bio (2)

  • ATB-330

    Product ATB-330

    [ALK5 inhibitor / Small Molecule / Develop for IPF and Fibrosis) – Complete to derivate the lead compound

    1. Confirm the highest ALK5 selectivity with superior efficacy and PK profile through in-vivo tests compared to competitors (small molecule new drugs) 
    ...
  • ATB-101

    Product ATB-101

    [ARB+SGLT-2i Fixed Dose Combination] – In process of Phase 3 clinical trial on approx. 250 patients
    1. The first Fixed Dose Combination treating hypertension and type 2 diabetes by a tablet in the world

    2. Expect the synergistic effect in the treatment of hypertension though mi...

Autotelic Bio resources (1)